APA (7th ed.) Citation

Saji, A. S., Yang, B., Yang, B., Hou, W. T., Liu, X., Ren, Q. P., . . . Yang, X. (2023, January). Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review. Frontiers in Oncology.

Chicago Style (17th ed.) Citation

Saji, Alen Sam, Biao Yang, Biao Yang, Wan Ting Hou, Xia Liu, Qiu Ping Ren, Yuan Feng Wei, Yu Zu Zhang, and Xi Yang. "Combined NK-CIK and PD-1 Inhibitor (nivolumab), an Effective Immunotherapy for Treating Intrahepatic Lymphoepithelioma-like Cholangiocarcinoma Unassociated with EBV Infection: Two Case Reports and a Literature Review." Frontiers in Oncology Jan. 2023.

MLA (9th ed.) Citation

Saji, Alen Sam, et al. "Combined NK-CIK and PD-1 Inhibitor (nivolumab), an Effective Immunotherapy for Treating Intrahepatic Lymphoepithelioma-like Cholangiocarcinoma Unassociated with EBV Infection: Two Case Reports and a Literature Review." Frontiers in Oncology, Jan. 2023.